Endocrinology

Help Shape the Future of Denosumab Treatment

As biosimilars enter the denosumab landscape, your perspective as a healthcare provider is critical in understanding what factors influence treatment decisions. This brief survey explores your views on reimbursement considerations, coding challenges, switching comfort, and drivers of biosimilar choice. As a thank you, by completing the survey, you’ll be entered into a drawing for a chance to win a $200 gift card.

Take the survey now and make your voice heard

Latest News

FDA Clears Omnipod 5 Algorithm Updates, Adding 100 mg/dL Target Glucose Option
FDA Clears Omnipod 5 Algorithm Updates, Adding 100 mg/dL Target Glucose Option

December 4th 2025

Insulet enhances the Omnipod® 5 system with new glucose targets and algorithms, improving insulin delivery for diabetes management.

Obesity Linked to Faster Alzheimer’s Disease Progression in Longitudinal Blood Biomarker Analysis / image credit Cyrus Raji, MD, PhD  Courtesy of RSNA
Obesity Linked to Faster Alzheimer Disease Progression in Longitudinal Blood Biomarker Analysis

December 2nd 2025

WHO Issues First Global Guidelines on GLP-1 Receptor Agonists for Obesity Treatment / image credit ©World Health Organization
WHO Issues First Guidelines on GLP-1 Receptor Agonists for Obesity Treatment

December 2nd 2025

Perimenopause Comes with "Feast-and-Famine" Swings in Hormone Levels, Says Gynecologist Bruce Dorr, MD
Perimenopause Comes with "Feast-and-Famine" Swings in Hormone Levels, Says Gynecologist Bruce Dorr, MD

November 21st 2025

Dual GCG/GLP-1 Agonist Mazdutide 9 mg Produces 20% Weight Loss in Phase 3 Trial of Chinese Adults with Obesity / image courtesy of Courtesy of Peking University Health Science Center
Dual GCG/GLP-1 Agonist Mazdutide 9 mg Produces 20% Weight Loss in Phase 3 Trial of Chinese Adults with Obesity

November 20th 2025

Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.